EUVIMEDEUVIMED entdecken
Crossref

L26/P-792 Controlled Ovarian Hyperstimulation in the Era of Oral Elagolix: A Comparative Study with Cetrorelix

A. Jain, R. Vembu, M. Pandurangi

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.1119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von A. Jain und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Can oral antagonist, provide effective pituitary suppression comparable to the standard injectable antagonist without compromising oocyte and embryo quality in IVF/ICSI cycles? Summary answer Oral elagolix achieves effective pituitary suppression with significantly lower LH and Estradiol levels than cetrorelix, while maintaining comparable oocyte yield, fertilization, and embryo quality. What is known already Gonadotropin-releasing hormone (GnRH) antagonists are essential in assisted reproductive technology (ART) to prevent premature luteinizing hormone (LH) surge during controlled ovarian stimulation. Daily subcutaneous injectable antagonists are most commonly used, but are costly and is associated with patient discomfort, injection-site reactions, and hence poor compliance. Elagolix, an oral GnRH antagonist approved for endometriosis, has shown rapid, reversible suppression of LH and estradiol. However, its application and direct comparison against the gold-standard injectable antagonists in COS is not yet well-established. Limited studies suggest that elagolix offers comparable suppression and IVF outcomes to injectables, while providing better patient convenience and reduced cost. Study design, size, duration This is a prospective, comparative, single-center study conducted at a tertiary fertility center from April 2025 to January 2026. A total of 220 patients undergoing IVF/ICSI cycles were enrolled and allocated into two groups: the study group (n = 110) receiving oral elagolix and the control group (n = 110) receiving subcutaneous cetrorelix for the prevention of premature LH surge. Statistical analysis utilized appropriate tests for continuous and categorical variables, with significance set at p < 0.05. Participants/materials, setting, methods Patients underwent controlled ovarian stimulation with rFSH/HMG as per department protocol. Antagonist was introduced when follicles reached ≥14 mm. Trigger was planned when >2 follicles exceeded 18 mm. On trigger day, serum LH, estradiol (E2), and progesterone (P4) were measured. Oocyte retrieval was planned 35–36 hours post-trigger. Primary outcomes were serum LH, E2 and P4 levels on trigger day. Secondary outcomes included oocytes retrieved, MII count, fertilization rate, and embryo quality. Main results and the role of chance Baseline characteristics (mean age, BMI, AMH, duration and cause of infertility) were comparable between groups. There were no significant differences in the mean duration of stimulation, total dose of gonadotropins, number of follicles ≥14 mm, and type of trigger. On the day of the trigger, the Elagolix group demonstrated significantly lower mean serum LH levels (0.7 ± 0.2 mIU/mL vs. 1.7 ± 1.2 mIU/mL; p < 0.05) and serum E2 levels (1910 ± 1080 pg/mL vs. 2820 ± 840 pg/mL; p < 0.05) compared to the Cetrorelix group, demonstrating superior suppression, while P4 was comparable. Despite this hormonal difference, key clinical outcomes remained comparable. The mean number of oocytes retrieved (17.5 ± 5.3 vs. 18.4 ± 5.0), the number of MII oocytes (13.5 ± 4.5 vs. 14.1 ± 4.2), and the fertilization rate (70% vs 72%) were not statistically different between the two groups. Furthermore, the number and quality of embryos (grade 1 embryos 65% vs 64.2%) were also similar. Limitations, reasons for caution The primary limitations are the relatively small sample size and the single-center design, which may affect the generalizability of the findings. The study is ongoing, and the current analysis does not include final reproductive outcomes such as clinical pregnancy and live birth rates, which are crucial for a comprehensive evaluation Wider implications of the findings Oral elagolix provides effective pituitary suppression without compromising oocyte or embryo quality. Its oral route improves patient convenience and reduces cost, representing a viable, patient-friendly alternative to injectables for COS. However, further studies are required to support wider clinical application and to establish its long-term efficacy and safety. Trial registration number No

Zitieren

APA

Jain, A., Vembu, R., & Pandurangi, M. (2026). L26/P-792 Controlled Ovarian Hyperstimulation in the Era of Oral Elagolix: A Comparative Study with Cetrorelix. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1119

Vancouver

Jain A, Vembu R, Pandurangi M. L26/P-792 Controlled Ovarian Hyperstimulation in the Era of Oral Elagolix: A Comparative Study with Cetrorelix. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1119

BibTeX
@article{Jain2026,
  author = {Jain, A. and Vembu, R. and Pandurangi, M.},
  title = {L26/P-792 Controlled Ovarian Hyperstimulation in the Era of Oral Elagolix: A Comparative Study with Cetrorelix},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.1119}
}
Kostenlos starten →